Marder SR, Cannon TD, 2019, Schizophrenia. N Engl J Med, 381(18): 1753–1761.

Desai PR, Lawson KA, Barner JC, et al., 2013, Identifying Patient Characteristics Associated With High Schizophrenia-Related Direct Medical Costs in Community-Dwelling Patients. J Manag Care Pharm, 19(6): 468–477.

Jauhar S, Johnstone M, McKenna PJ, 2022, Schizophrenia. Lancet, 399(10323): 473–486.

Hjorthoj C, Sturup AE, McGrath JJ, et al., 2017, Years of Potential Life Lost and Life Expectancy in Schizophrenia: A Systematic Review and Meta-Analysis. Lancet Psychiatry, 4(4): 295–301.

Kahn RS, 2020, On the Origins of Schizophrenia. Am J Psychiatry, 177(4): 291–297.

McCutcheon RA, Reis Marques T, Howes OD, 2020, Schizophrenia—An Overview. JAMA Psychiatry, 77(2): 201–210.

Oxenkrug G, Forester B, 2024, Anthranilic Acid, a GPR109A Agonist, and Schizophrenia. Int J Tryptophan Res, 17: 11786469241239125.

Almond S, Knapp M, Francois C, et al., 2004, Relapse in Schizophrenia: Costs, Clinical Outcomes and Quality of Life. Br J Psychiatry, 184: 346–351.

Barlati S, Nibbio G, Vita A, 2021, Schizophrenia During the COVID-19 Pandemic. Curr Opin Psychiatry, 34(3): 203–210.

Tuckson RV, Edmunds M, Hodgkins ML, 2017, Telehealth. N Engl J Med, 377(16): 1585–1592.

National Nursing Career Development Plan 2021–2025, 2022, Chinese Nursing Management, 22(6): 801–804.

Kasckow J, Felmet K, Appelt C, et al., 2014, Telepsychiatry in the Assessment and Treatment of Schizophrenia. Clin Schizophr Relat Psychoses, 8(1): 21–27.

Sood S, Mbarika V, Jugoo S, et al., 2007, What Is Telemedicine? A Collection of 104 Peer-Reviewed Perspectives and Theoretical Underpinnings. Telemed J E Health, 13(5): 573–590.

Centers for Disease Control and Prevention, 2017, National Center for Health Statistics. U.S. Department of Health and Human Services.

Lawes-Wickwar S, McBain H, Mulligan K, 2018, Application and Effectiveness of Telehealth to Support Severe Mental Illness Management: Systematic Review. JMIR Ment Health, 5(4): e62.

Comendador L, Cebria AI, Sanz A, et al., 2023, Telephone-Delivered Interventions for Suicide Prevention in Schizophrenia and Related Disorders: A Systematic Review. Healthcare (Basel), 11(3), 432.

Santesteban-Echarri O, Piskulic D, Nyman RK, et al., 2020, Telehealth Interventions for Schizophrenia-Spectrum Disorders and Clinical High-Risk for Psychosis Individuals: A Scoping Review. J Telemed Telecare, 26(1–2): 14–20.

OReilly R, Bishop J, Maddox K, et al., 2007, Is Telepsychiatry Equivalent to Face-To-Face Psychiatry? Results From a Randomized Controlled Equivalence Trial. Psychiatr Serv, 58(6): 836–843.

Cairns AJJ, Kelly J, Taylor CDJ, 2023, Assessing the Delivering of iMAgery-Focused Therapy for PSychosis (iMAPS) via Telehealth. Psychol Psychother, 96(3): 678–696.

Sharp IR, Kobak KA, Osman DA, 2011, The Use of Videoconferencing With Patients With Psychosis: A Review of the Literature. Ann Gen Psychiatry, 10(1): 14.

Tian Y, Zhang S, Huang F, et al., 2021, Comparing the Efficacies of Telemedicine and Standard Prenatal Care on Blood Glucose Control in Women With Gestational Diabetes Mellitus: Randomized Controlled Trial. JMIR Mhealth Uhealth, 9(5): e22881.

Li M, Chen Y, Hu X, et al., 2023, The Preferences for Telemedicine and Standard Health Care Services From the Perspective of Patients With Schizophrenia. BMC Psychiatry, 23(1): 361.

Bucci S, Barrowclough C, Ainsworth J, et al., 2018, Actissist: Proof-of-Concept Trial of a Theory-Driven Digital Intervention for Psychosis. Schizophr Bull, 44(5): 1070–1080.

Palmier-Claus JE, Ainsworth J, Machin M, et al., 2012, The Feasibility and Validity of Ambulatory Self-Report of Psychotic Symptoms Using a Smartphone Software Application. BMC Psychiatry, 12: 172.

Lewis S, Ainsworth J, Sanders C, et al., 2020, Smartphone-Enhanced Symptom Management in Psychosis: Open, Randomized Controlled Trial. J Med Internet Res, 22(8): e17019.

Godfrey A, Hetherington V, Shum H, et al., 2018, From A to Z: Wearable Technology Explained. Maturitas, 113: 40–47.

Chong KPL, Guo JZ, Deng X, et al., 2020, Consumer Perceptions of Wearable Technology Devices: Retrospective Review and Analysis. JMIR Mhealth Uhealth, 8(4): e17544.

Cella M, He Z, Killikelly C, et al., 2019, Blending Active and Passive Digital Technology Methods to Improve Symptom Monitoring in Early Psychosis. Early Interv Psychiatry, 13(5): 1271–1275.

Schlier B, Krkovic K, Clamor A, et al., 2019, Autonomic Arousal During Psychosis Spectrum Experiences: Results From a High-Resolution Ambulatory Assessment Study Over the Course of Symptom On- and Offset. Schizophr Res, 212: 163–170.

Cella M, Okruszek L, Lawrence M, et al., 2018, Using Wearable Technology to Detect the Autonomic Signature of Illness Severity in Schizophrenia. Schizophr Res, 195: 537–542.

Firth J, Torous J, 2015, Smartphone Apps for Schizophrenia: A Systematic Review. JMIR Mhealth Uhealth, 3(4): e102.

Krzystanek M, Borkowski M, Skalacka K, et al., 2019, A Telemedicine Platform to Improve Clinical Parameters in Paranoid Schizophrenia Patients: Results of a One-Year Randomized Study. Schizophr Res, 204: 389–396.

Ben-Zeev D, Brenner CJ, Begale M, et al., 2014, Feasibility, Acceptability, and Preliminary Efficacy of a Smartphone Intervention for Schizophrenia. Schizophr Bull, 40(6): 1244–1253.

Macias C, Panch T, Hicks YM, et al., 2015, Using Smartphone Apps to Promote Psychiatric and Physical Well-Being. Psychiatr Q, 86(4): 505–519.

Pratt SI, Bartels SJ, Mueser KT, et al., 2013, Feasibility and Effectiveness of an Automated Telehealth Intervention to Improve Illness Self-Management in People With Serious Psychiatric and Medical Disorders. Psychiatr Rehabil J, 36(4): 297–305.

Higashi K, Medic G, Littlewood KJ, et al., 2013, Medication Adherence in Schizophrenia: Factors Influencing Adherence and Consequences of Nonadherence, A Systematic Literature Review. Ther Adv Psychopharmacol, 3(4): 200–218.

Lacro JP, Dunn LB, Dolder CR, et al., 2002, Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature. J Clin Psychiatry, 63(10): 892–909.

Gray R, Bressington D, Ivanecka A, et al., 2016, Is Adherence Therapy an Effective Adjunct Treatment for Patients With Schizophrenia Spectrum Disorders? A Systematic Review and Meta-Analysis. BMC Psychiatry, 16: 90.

Stentzel U, Van Den Berg N, Schulze LN, et al., 2018, Predictors of Medication Adherence Among Patients With Severe Psychiatric Disorders: Findings From the Baseline Assessment of a Randomized Controlled Trial (Tecla). BMC Psychiatry, 18(1): 155.

Tamene FB, Mihiretie EA, Mulugeta A, et al., 2024, Medication Non-Adherence and Associated Factors Among People With Schizophrenia: Multicenter Cross-Sectional Study in Northwest Ethiopia. BMC Psychiatry, 24(1): 567.

Velligan D, Mintz J, Maples N, et al., 2013, A Randomized Trial Comparing In-Person and Electronic Interventions for Improving Adherence to Oral Medications in Schizophrenia. Schizophr Bull, 39(5): 999–1007.

Huang A, 2022, Influence of Remote Health Management Model on Self-Efficacy and Compliance Behavior of Patients With Schizophrenia in Stable Stage. Chinese Evidence-Based Nursing, 8(6): 785–789.

Sher L, Kahn RS, 2019, Suicide in Schizophrenia: An Educational Overview. Medicina (Kaunas), 55(7), 361.

Flaherty LR, Daniels K, Luther J, et al., 2017, Reduction of Medical Hospitalizations in Veterans With Schizophrenia Using Home Telehealth. Psychiatry Res, 255: 153–155.

Kasckow J, Zickmund S, Gurklis J, et al., 2016, Using Telehealth to Augment an Intensive Case Monitoring Program in Veterans With Schizophrenia and Suicidal Ideation: A Pilot Trial. Psychiatry Res, 239: 111–116.

Kasckow J, Gao S, Hanusa B, et al., 2015, Telehealth Monitoring of Patients With Schizophrenia and Suicidal Ideation. Suicide Life Threat Behav, 45(5): 600–611.

Fleischmann A, Bertolote JM, Wasserman D, et al., 2008, Effectiveness of Brief Intervention and Contact for Suicide Attempters: A Randomized Controlled Trial in Five Countries. Bull World Health Organ, 86(9): 703–709.

Eisner E, Drake R, Barrowclough C, 2013, Assessing Early Signs of Relapse in Psychosis: Review and Future Directions. Clin Psychol Rev, 33(5): 637–653.

Csernansky JG, Schuchart EK, 2002, Relapse and Rehospitalization Rates in Patients With Schizophrenia: Effects of Second-Generation Antipsychotics. CNS Drugs, 16(7): 473–487.

Green MF, Horan WP, Lee J, et al., 2018, Social Disconnection in Schizophrenia and the General Community. Schizophr Bull, 44(2): 242–249.

Torous J, Firth J, Mueller N, et al., 2017, Methodology and Reporting of Mobile Health and Smartphone Application Studies for Schizophrenia. Harv Rev Psychiatry, 25(3): 146–154.

Buck B, Scherer E, Brian R, et al., 2019, Relationships Between Smartphone Social Behavior and Relapse in Schizophrenia: A Preliminary Report. Schizophr Res, 208: 167–172.

Eisner E, Drake RJ, Berry N, et al., 2019, Development and Long-Term Acceptability of ExPRESS, a Mobile Phone App to Monitor Basic Symptoms and Early Signs of Psychosis Relapse. JMIR Mhealth Uhealth, 7(3): e11568.

Ybarra ML, Rodriguez K, Madison H, et al., 2019, Developing Texting for Relapse Prevention: A Scalable mHealth Program for People With Schizophrenia and Schizoaffective Disorder. J Nerv Ment Dis, 207(10): 854–862.

Ybarra ML, Rodriguez KM, Fehmie DA, et al., 2022, Acceptability of Texting 4 Relapse Prevention, Text Messaging-Based Relapse Prevention Program for People With Schizophrenia and Schizoaffective Disorder. J Nerv Ment Dis, 210(2): 123–128.

Cui F, Ma Q, He X, et al., 2020, Implementation and Application of Telemedicine in China: Cross-Sectional Study. JMIR Mhealth Uhealth, 8(10): e18426.

Lin JC, Kavousi Y, Sullivan B, et al., 2020, Analysis of Outpatient Telemedicine Reimbursement in an Integrated Healthcare System. Ann Vasc Surg, 65: 100–106.